# Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

> **NCT04693039** · PHASE1 · COMPLETED · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 40 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Phenlarmide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04693039
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-23
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04693039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04693039, "Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT04693039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*